European Union supports proteomics research - Ten million euro for access to European proteomics facilities

The European Union has awarded 10 million euro to a consortium of eighteen European research groups in the field of mass spectrometry based proteomics research throughout Europe. The European Proteomics Initiative Consortium (EPIC-XS) started on the first of January 2019 and will run for a period of four years. At the Technical University of Munich (TUM) the project is coordinated by Prof. Bernhard Küster, Professorship of Proteomics and Bioanalytics.

PhD student Svenja Petzold at a high-throughput mass spectrometer of the professorship of Proteomics and Bioanalytics. (Image: B. Küster / TUM)

Proteomics, the large-scale study of proteins and their role in living cells and organisms, is an important technology used to gain insight into the function of biological systems and the roles they play in health and disease.

Mass spectrometry based proteomics requires state of the art technology, in-house technical know-how, sustainable and robust workflow practices, successful and correct data interpretation, and data management. Therefore, researchers often depend on dedicated proteomics facilities to get access to proteomics technology.

State of the art proteomics equipment

The EPIC-XS initiative will support researchers, by providing them with access to such state of the art proteomics equipment, and allowing them to submit research proposals that make use of the proteomics technology offered by the project. All submitted proposals will be peer-reviewed and the best projects will be selected for access to facilities of the EPIC-XS consortium.

This initiative is a follow-up of the previous European proteomics infrastructure project PRIME-XS, which was completed in 2015. EPIC-XS will again provide access to proteomics facilities throughout Europe, supporting and expanding the European proteomics community through its expertise in proteomics. The provision of courses and training programs, will enable new research communities to be schooled in advanced proteomics technologies.

The EPIC-XS consortium consists of partners throughout Europe which have a proven track record in facilitating national and international research within their institutions. All partners share a common goal: to facilitate the development and sustainability of proteomics exploration to all life science researchers within the European Union.

More information:

The EPIC-XS initiative includes Utrecht University (coordinator), University of Bergen, University of Copenhagen, European Bioinformatics Institute (Cambridge), University of Cambridge, Flemish Institute for Biotechnology (Gent), Institut Pasteur (Paris), Functional Genomics Center (Zurich), Spanish National Cancer Research Centre (Madrid), Centre for Genomic Regulation (Barcelona), Royal Institute of Technology (Stockholm), University of Tartu (Estland), Institute of Microbiology (Prague), Eberhard-Karls-University Tübingen, Technical University of Munich, Research Institute of Molecular Pathology (Vienna), European Institute of Oncology (Milan) and Foundation of Research and Technology Hellas (Iraklio, Crete).Starting in the spring of 2019, requests for access to the facilities can be submitted via www.epic-xs.eu.

Contact:

Prof. Dr. Bernhard Küster
Technical University of Munich
Chair of Proteomics and Bioanalytics

Phone: +49/8161/71 56 97
E-mail: kuster[at]tum.de
Web: https://proteomics.wzw.tum.de